CCL2 and malignant colon neoplasm: In mice with AOM/DSS-induced colon cancer, oral supplementation with a δ/γ-tocotrienol 0.035% (~2.2 μmoles daily) and δ-tocotrienol-13-COOH 0.04% (~2.3 μmoles daily) diet led to a decrease in pro-inflammatory cytokines, such as GM-CSF and MCP-1, in the δ-tocotrienol-13-COOH-treated group, and a decrease in IL-1β in the δ-T3-treated group compared with the negative control group [53].